WNT5A and apparent mineralocorticoid excess: Wnt5a immunoexpression identified in half of the cases of AME may express both its activating and inactivating role; and Wnt5a immunoexpression identified in all cases of CCOT may express a balance between the activator Wnt1 and the inactivator Wnt5a in CCOT.